chartexchange

Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ...

GuruFocus | Nov 10, 2026 6:02 AM EST

Bicara Therapeutics Inc (BCAX) advances its pivotal FORTIFY-HN01 study toward a mid-2027 interim readout while reporting durable Phase 1b responses and a cash runway extending into 2029. Related Stocks: BCAX ,

Read original article